IRLAB to present at Redeye Investor Forum

Gothenburg, Sweden, April 16, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will present at Redeye Investor Forum on April 18.

IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam

IRLAB’s mesdopetam displays antipsychotic properties in an advanced model of Parkinson’s disease psychosis